Company intelligence / Profile preview
Kriya Therapeutics, Inc.
Palo Alto, California, United Stateskriyatx.com ↗
- Ownership
- Private
- Employees
- ~160
- Development stage
- Preclinical
01
Overview
Kriya is advancing multiple gene therapy programs across three therapeutic areas, with the first program expected to enter the clinic in 2024 and up to five programs anticipated to be in clinical trials by the end of 2025[5].
- Therapeutic areas
- OphthalmologyEndocrinologyNeurologyMetabolic Disorders
- Modalities
- AAV-based gene therapies
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
EveradsTwist (antibody discovery agreement)
Beyond the preview
Go deeper on Kriya Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kriya Therapeutics, Inc..